Characterization of receptors for two Xenopus gastrointestinal tachykinin peptides in their species of origin.
Two tachykinin peptides, bufokinin and Xenopus neurokinin A (X-NKA) were recently isolated from Xenopus laevis. In this study we investigated the tachykinin receptors in the Xenopus gastrointestinal tract. In functional studies using stomach circular muscle strips, all peptides had similar potencies (EC50 values 1-7 nM). The rank order of potency to contract the intestine was physalaemin (EC50 1 nM)> or =bufokinin (EC50 3 nM)>substance P (SP)> or =cod SP>NKA>>X-NKA (EC50 1,900 nM). No maximum response could be obtained for [Sar9,Met(O2)11]SP, eledoisin and kassinin. In stomach strips, the mammalian tachykinin receptor antagonists RP 67580 (NK1) and MEN 10376 (NK2) had agonistic effects but did not antagonize bufokinin or X-NKA. In intestinal strips, RP 67580 (1 microM) reduced the maximal response to X-NKA but not bufokinin, while MEN 10376 was ineffective. [125I]BH-bufokinin bound with high affinity to a single class of sites, of KD 213+/-35 (stomach) and 172+/-9.3 pM (intestine). Specific binding of [125I]BH-bufokinin was displaced by bufokinin> or =SP>NKA> or =eledoisin approximately kassinin>X-NKA, indicating binding to a tachykinin NK1-like receptor. Selective tachykinin receptor antagonists were weak or ineffective. Other iodinated tachykinins ([125I]NKA and [125I]BH-eledoisin) displayed biphasic competition profiles, with the majority of sites preferring bufokinin rather than X-NKA. In conclusion, there is evidence for two different tachykinin receptors in Xenopus gastrointestinal tract. Both receptors may exist in stomach, whereas the bufokinin-preferring NK1-like receptor predominates in longitudinal muscle of the small intestine. Antagonists appear to interact differently with amphibian receptors, compared with mammalian receptors.
Johansson
Agot
A
Department of Zoophysiology, University of Göteborg, Box 463, SE-405 30, Sweden.
Liu
Lu
L
Holmgren
Susanne
S
Burcher
Elizabeth
E
D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D002299:Cardia / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004600:Eledoisin / Q000494:pharmacology; D005260:Female; D007211:Indoles / Q000494:pharmacology; D036341:Intercellular Signaling Peptides and Proteins / Q000737:chemistry / Q000494:pharmacology; D007421:Intestine, Small / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D007457:Iodine Radioisotopes; D054833:Isoindoles; D015286:Kassinin / Q000494:pharmacology; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D015288:Neurokinin A / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010803:Physalaemin / Q000031:analogs & derivatives* / Q000494:pharmacology; D018039:Receptors, Tachykinin / Q000737:chemistry* / Q000187:drug effects* / Q000502:physiology; D013045:Species Specificity; D013373:Substance P / Q000031:analogs & derivatives* / Q000494:pharmacology; D014981:Xenopus / Q000378:metabolism*
D007211:Indoles; D036341:Intercellular Signaling Peptides and Proteins; D007457:Iodine Radioisotopes; D054833:Isoindoles; D010446:Peptide Fragments; D018039:Receptors, Tachykinin; C112071:bufokinin; C062618:substance P, Sar(9)-Met(O2)(11)-; C079014:GR 82334; C069192:neurokinin A(4-10), Tyr(5)-Trp(6,8,9)-Lys(10)-; C071693:7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; D010803:Physalaemin; D013373:Substance P; D015286:Kassinin; D004600:Eledoisin; D015288:Neurokinin A